By Research Area
Hot products 
-
Mouse Anti-EIF4G1 Recombinant Antibody (2A9) (CBMAB-A2544-LY)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7697) (CBMAB-1869CQ)
-
Mouse Anti-ADIPOR1 Recombinant Antibody (V2-179982) (CBMAB-A1368-YC)
-
Mouse Anti-GLP1R Recombinant Antibody (4F3) (CBMAB-G0521-LY)
-
Mouse Anti-EMP3 Recombinant Antibody (CBFYE-0100) (CBMAB-E0207-FY)
-
Rabbit Anti-BRCA2 Recombinant Antibody (D9S6V) (CBMAB-CP0017-LY)
-
Mouse Anti-ENO2 Recombinant Antibody (85F11) (CBMAB-0276CQ)
-
Mouse Anti-C5AR1 Recombinant Antibody (R63) (CBMAB-C9553-LY)
-
Mouse Anti-CD59 Recombinant Antibody (CBXC-2097) (CBMAB-C4421-CQ)
-
Mouse Anti-A2M Recombinant Antibody (V2-178822) (CBMAB-A0036-YC)
-
Mouse Anti-CEMIP Recombinant Antibody (3C12) (CBMAB-K0296-LY)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CBC05) (CBMAB-CR005LY)
-
Rat Anti-C5AR1 Recombinant Antibody (8D6) (CBMAB-C9139-LY)
-
Mouse Anti-EGR1 Recombinant Antibody (CBWJZ-100) (CBMAB-Z0289-WJ)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CR3022) (CBMAB-CR014LY)
-
Mouse Anti-DLC1 Recombinant Antibody (D1009) (CBMAB-D1009-YC)
-
Mouse Anti-APP Recombinant Antibody (5C2A1) (CBMAB-A3314-YC)
-
Mouse Anti-BZLF1 Recombinant Antibody (BZ.1) (CBMAB-AP705LY)
-
Mouse Anti-AAV9 Recombinant Antibody (V2-634029) (CBMAB-AP023LY)
-
Mouse Anti-CD24 Recombinant Antibody (2Q1282) (CBMAB-C1624-CN)
Explore High-Affinity Antibody by Tumor Type
The paradigm of modern oncology has shifted definitively from broad-spectrum cytotoxic approaches to precision medicine, driven by a granular understanding of tumor heterogeneity. Cancer is not a monolithic disease, but a constellation of distinct pathologies defined by their tissue of origin, driver mutations, and the unique architecture of the Tumor Microenvironment (TME). To facilitate targeted therapeutic discovery, researchers must navigate specific molecular signatures inherent to each histological subtype.
In the realm of hormone-driven malignancies, particularly Breast and Prostate cancers, current research focuses heavily on resistance mechanisms in hormone receptor signaling and the interrogation of DNA damage response pathways (e.g., BRCA1/2). Conversely, high-mortality solid tumors such as Lung, Colorectal, and Pancreatic carcinomas present unique challenges related to metabolic reprogramming and dense desmoplastic stroma that impedes drug delivery. Unlocking the signaling cascades of KRAS, EGFR, and p53 in these tissues remains a priority for the development of next-generation inhibitors. Distinct immunological profiles are observed in Melanoma, which has served as the proving ground for checkpoint blockade immunotherapies, and Glioma, where the blood-brain barrier and a highly immunosuppressive myeloid landscape complicate treatment. Furthermore, the study of Ovarian cancer continues to highlight the importance of early detection biomarkers, while Hematologic malignancies—spanning leukemias, lymphomas, and myelomas—drive innovation in CAR-T cell therapies and the understanding of hematopoietic stem cell niches.
Empowering Discovery with Comprehensive Research
At Creative Biolabs, we recognize that the reproducibility of translational research hinges on both the fidelity of your reagents and the depth of your scientific resources. To support the rigorous demands of cancer biology, we offer a holistic platform that extends beyond our comprehensive portfolio of high-affinity antibodies. Whether characterizing surface antigens in flow cytometry, mapping spatial protein expression via immunohistochemistry (IHC), or quantifying signaling phosphorylation in Western blot, our tools are complemented by a wealth of technical and educational support.
We assist your investigation into complex oncogenic mechanisms by providing curated scholarly articles, detailed signaling pathway maps, and optimized laboratory protocols. This integrated ecosystem is designed to streamline your workflow from target identification to validation. By combining reagents of exceptional lot-to-lot consistency with expert knowledge resources, Creative Biolabs empowers scientists to dissect the complexities of specific tumor types with confidence, accelerating the journey from benchside discovery to clinical breakthrough.
Browse by Tumor Type
Products List
Loading...
Compare
